RPG Life Sciences plans to invest about Rs 60 over three years to enter specialised oncology and psychiatry drug segments, its top official said late on Monday.

"The sales (in these segments) are rising more than 20% annually and hence they present an immense growth opportunity," AS Chouhan, managing director, told Reuters in an interview, adding that these segments are valued at Rs 3570 crore in India.

RPG Life plans Rs 600 million capex for new biz

RPG Life plans to launch nine new products in these two segments in July, he said.

"We have made in all 40 filings with the (US) FDA so far," he added.

RPG Life Sciences, a part of the Rs 16000 crore RPG group, which has interests in tyres, energy, infrastructure, information technology and other sectors, reported sales of Rs 163 crore on net profit of Rs 10.8 crore for in FY10.

"The new drugs being launched are expected to boost revenues in the next financial year (FY12) and not the current," he added.

Along with drug launches, RPG Life Sciences is also exploring options to set up a drug-delivery service.